Recent Updates
Recently added Catalysts
BMY Positive Sentiment

Bristol Myers Squibb Presents First Clinical Data from Two Phase 3 Studies in the ADEPT Program Evaluating KarXT for Psychosis Associated with Alzheimer’s Disease

Key Takeaway: Bristol Myers Squibb presented initial clinical data from two Phase 3 studies in the ADEPT program. The studies evaluate KarXT for treating psychosis associated with Alzheimer's disease. This marks a significant step in exploring new treatment options for patients suffering from this condition.

Market Sentiment Analysis

POSITIVE FACTORS

  • First clinical data presented from Phase 3 studies
  • Focus on KarXT for Alzheimer's-related psychosis
  • Potential advancement in Alzheimer's treatment

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+19%
120-day peak, hindsight
Typical move
1.7%
average across 15 past catalysts
Lead asset
Mezigdomide
NDA/BLA · Relapsed or Refractory Multiple Myeloma

Full Press Release Details

PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #ADEPT--BMS Presents First Clinical Data from Two Phase 3 Studies in the ADEPT Program Evaluating KarXT for Psychosis Associated with Alzheimer’s Disease

Frequently Asked Questions

What is the ADEPT program?

The ADEPT program evaluates KarXT for psychosis associated with Alzheimer's disease.

What did BMS present?

BMS presented initial clinical data from two Phase 3 studies.

What is KarXT used for?

KarXT is being evaluated for treating psychosis in Alzheimer's patients.

What phase are the studies in?

The studies are in Phase 3 of clinical trials.

Last updated: Nov 18, 2026